GILD vs NVO

Gilead Sciences and Novo Nordisk A/S, both Healthcare

Novo Nordisk A/S is the larger company at $211B against $154B. Over the past year GILD returned +36% against -35% for NVO. The RyuScore puts NVO ahead, 88 against 44 out of 100.

Gilead Sciences and Novo Nordisk A/S compared on valuation, return and the RyuScore
FigureGILDNVO
Last close$151$38.62
Market cap$154B$211B
Dividend yield2.1%n/a
1-year return+36%-35%
5-year return+155%-15%
RyuScoresector-relative, 1–1044/10088/100

Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.

Gilead Sciences

Revenue of $7.8B in Q2 2026, net income null. Its largest reported line is HIV Product Sales, 55% of the disclosed total.

GILD overviewrevenue and segmentsvaluation

Novo Nordisk A/S

NVO overviewrevenue and segmentsvaluation

Open these two in the interactive comparison to add more names, change the period or see the correlation.